Production (Stage)
Alto Neuroscience, Inc.
ANRO
$3.03
$0.103.41%
NYSE
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | 0.21% | 9.43% | -4.70% | -19.48% | -19.61% |
Total Depreciation and Amortization | 0.59% | 39.34% | 7.96% | 16.49% | -13.39% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 62.27% | -11.07% | -23.06% | 7.75% | 251.70% |
Change in Net Operating Assets | -4,806.06% | -96.45% | 94.83% | 660.78% | 77.94% |
Cash from Operations | -27.15% | -11.04% | -0.27% | -6.47% | 4.69% |
Capital Expenditure | 95.26% | 49.65% | -195.59% | -51.79% | 36.36% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | 95.26% | 49.65% | -195.59% | -51.79% | 36.36% |
Total Debt Issued | 1,475.04% | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 304.08% | -26.87% | 9.84% | -99.96% | 474,344.83% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 56.32% | -200.00% | 523.73% | 90.26% | -59.73% |
Cash from Financing | 18,526.53% | -96.28% | 662.82% | -100.17% | 211.97% |
Foreign Exchange rate Adjustments | -466.67% | 185.71% | -40.00% | 0.00% | -225.00% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 44.51% | -17.96% | 6.94% | -109.95% | 294.58% |